Customer Concentration

3 Months Ended

Mar. 31, 2018

Customer Concentration [Abstract]

Concentration Risk Disclosure [Text Block]

6. Concentration of Credit Risk

Product Line Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues, was as follows:

		Three Months Ended March 31,
Licensee	Product Name	2018		2017
Biogen	Tysabri®	7	%	31	%
Depomed	Glumetza, Janumet XR, Jentadueto XR and Invokamet XR	19	%	14	%
N/A	Tekturna, Tekturna HCT, Rasilez and Rasilez HCT	48	%	28	%
kaléo	Interest revenues	—	%	10	%
LENSAR	LENSAR Laser System	13	%	—	%

__________________

N/A = Not applicable